{
  "pathway_name": "follicular-lymphoma-clinical-pathways-v3-2024",
  "original_file": "follicular-lymphoma-clinical-pathways-v3-2024_extracted.json",
  "processed_at": "2025-03-29T01:25:38.961085",
  "complete_summary": {
    "response": "# Comprehensive Clinical Pathway for Follicular Lymphoma Management\n\n## I. INTRODUCTION\nThis comprehensive clinical pathway provides evidence-based guidance for the diagnosis, treatment, and management of patients with follicular lymphoma (FL) at initial presentation through multiple relapses. The pathway addresses diagnostic workup, risk stratification, treatment options based on disease stage and prior therapies, surveillance recommendations, and supportive care measures.\n\n## II. VA PRESUMPTIVE SERVICE CONNECTION\n\n### Eligibility Categories\n1. **Atomic Veterans - Exposure to Ionizing Radiation**\n   - Covered condition: Lymphomas (other than Hodgkin's disease)\n\n2. **Gulf War and Post 9/11 Veterans**\n   - Service on/after September 11, 2001 in: Afghanistan, Djibouti, Egypt, Jordan, Lebanon, Syria, Uzbekistan, or Yemen\n   - OR\n   - Service on/after August 2, 1990 in: Southwest Asia theater of operations or Somalia\n\n3. **Southwest Asia Theater** includes:\n   - Iraq, Kuwait, Saudi Arabia, neutral zone between Iraq and Saudi Arabia\n   - Bahrain, Qatar, UAE, Oman\n   - Gulf of Aden, Gulf of Oman, Persian Gulf, Arabian Sea, Red Sea\n   - Airspace above these locations\n\n## III. DIAGNOSTIC APPROACH AND INITIAL ASSESSMENT\n\n### Essential Diagnostic Workup\n- **Biopsy**: Excisional lymph node biopsy preferred\n- **Grade Determination**:\n  * Grade 1-3a: Follow standard FL pathway\n  * Grade 3b: Follow DLBCL pathway\n\n### Standard Laboratory Testing\n- CBC with differential, CMP, uric acid, LDH\n- HBsAg, HBcAb, HBsAb, HCV antibody, HIV testing\n\n### Imaging Studies\n- Cross-sectional imaging: CT neck, chest, abdomen, pelvis with IV contrast or FDG-PET/CT\n- PET/CT preferred if transformation concern exists\n\n### Transformation Assessment\n- If clinically suspected: Perform PET/CT and biopsy of FDG-avid site\n- If confirmed transformation: Follow DLBCL treatment pathway\n\n## IV. FIRST-LINE TREATMENT\n\n### Limited Stage Disease (Stage I or Contiguous Stage II)\n- **Option 1**: Radiation therapy (24-30 Gy)\n- **Option 2**: Observation with monitoring every 3-6 months\n\n### Advanced Stage Disease\n1. **Evaluate for indications for therapy**:\n   - Local symptoms due to nodal disease\n   - Reduced organ function due to nodal disease\n   - B-symptoms (fever, weight loss, night sweats)\n   - Cytopenias (Hgb < 10 g/dL, platelets <100,000/mm\u00b3)\n   - Increase in disease tempo\n\n2. **If indications for therapy present**:\n   - **Recommended regimens** (shared decision-making with patient):\n     * Lenalidomide + rituximab (18 cycles)\n     * Bendamustine + obinutuzumab (6 cycles)\n   - Follow with monitoring every 3-6 months\n\n3. **If no indications for therapy**:\n   - Observation with monitoring every 3-6 months\n\n4. **Maintenance therapy consideration**:\n   - Rituximab every 8 weeks for 24 months improves progression-free survival\n   - Balance risks (including increased infection risk) and benefits for individual patients\n\n## V. SECOND-LINE TREATMENT (FIRST RELAPSE)\n\n### Initial Relapse Assessment\n- Clinical/laboratory workup\n- Review previous therapy response\n- Assessment for transformation to aggressive lymphoma\n\n### Treatment Decision Algorithm\n1. **Clinical trial eligibility assessment**\n   - If eligible \u2192 Refer to clinical trial (preferred option)\n\n2. **Treatment options based on prior therapy**:\n\n   **a. Previous alkylating agent + anti-CD20**:\n   - Bendamustine + rituximab (if prior therapy >24 months ago)\n   - Lenalidomide + rituximab\n   - PI3K inhibitors (idelalisib, copanlisib, duvelisib)\n   - Radioimmunotherapy (if eligible)\n   - EZH2 inhibitor (for patients with EZH2 mutation)\n\n   **b. Previous bendamustine + anti-CD20**:\n   - CHOP/CVP (if >24 months since prior treatment)\n   - Lenalidomide + rituximab\n   - PI3K inhibitors\n   - EZH2 inhibitor (for patients with EZH2 mutation)\n\n   **c. Previous CHOP/CVP + anti-CD20**:\n   - Bendamustine + rituximab (if >24 months since prior therapy)\n   - Lenalidomide + rituximab\n   - PI3K inhibitors\n   - EZH2 inhibitor (for patients with EZH2 mutation)\n\n## VI. MULTIPLY RELAPSED DISEASE MANAGEMENT\n\n### Initial Assessment\n- Cross-sectional imaging\n- Biopsy of accessible target tissue\n- Mandatory assessment for transformation\n\n### Treatment Algorithm\n1. **If transformation present**:\n   - Early referral for stem cell transplant or CAR-T therapy\n   - Follow DLBCL pathway\n\n2. **If no transformation**:\n   - Assess if prior therapy was low intensity (INT, single agent anti-CD20, chlorambucil)\n   - For patients with prior intensive therapy:\n     \n     **a. If unfavorable lymphoma**:\n     - Defined as: relapsed after anti-CD20, chemotherapy, and lenalidomide OR progression <24 months from all prior treatments\n     - Treatment options (after shared decision-making):\n       * Bendamustine-rituximab (4 cycles), OR\n       * Lenalidomide-rituximab\n     \n     **b. Evaluate for cellular therapy candidacy**:\n     - Candidate criteria:\n       * ECOG performance status 0-1\n       * Few or controlled comorbidities\n       * Younger age (typically <70 years)\n       * Patient/caregiver able to relocate if needed\n     \n     **c. If candidate for cellular therapy**:\n       * Refer for stem cell transplant or CAR-T therapy\n       * Assess for EZH2 mutation:\n         - If positive \u2192 Tazemetostat\n         - If negative \u2192 Zandelisib + obinutuzumab\n     \n     **d. If not a cellular therapy candidate**:\n       * Consider mosunetuzumab\n       * Monitor for progression\n\n     **e. If not unfavorable lymphoma**:\n       * Follow Indolent Follicular Lymphoma pathway\n\n## VII. MOLECULAR TESTING RECOMMENDATIONS\n\n### Testing by Clinical Scenario:\n\n1. **Suspected Pediatric-Type Follicular Lymphoma**\n   - **IHC**: BCL2 and BCL6\n   - **FISH**: t(14;18), BCL6, IRF4 or IGH rearrangements, 1p36\n   - Testing provider: Local VA or contracted vendor\n\n2. **Suspected Large B-Cell Lymphoma with IRF4 Rearrangement**\n   - **IHC**: BCL2, BCL6, CD10 and MUM1\n   - **FISH**: IRF4/MUM1 cryptic rearrangement with IGH\n   - Testing provider: Local VA or contracted vendor\n\n3. **Multiply Relapsed Follicular Lymphoma**\n   - **Molecular**: EZH2 mutation analysis (NPOP coverage available)\n   - Testing provider: Tempus or Foundation\n\n## VIII. SUPPORTIVE CARE AND SURVEILLANCE\n\n### Supportive Care Measures\n- **Hepatitis management**:\n  * HBV DNA testing if HBsAg or HBcAb positive\n  * Entecavir prophylaxis if HBsAg or HBcAb positive\n  * Hepatitis C antiviral treatment if appropriate\n\n- **Infection prevention**:\n  * COVID and pneumococcal vaccination recommended\n  * VZV/HSV and PJP prophylaxis with fludarabine-regimens or transplant candidates\n  * LVF prophylaxis with anthracyclines\n\n- **Regimen-specific prophylaxis**:\n  * VTE prophylaxis with lenalidomide\n  * G-CSF support for: age >70 years, pre-existing leukopenia, recent chemotherapy\n\n### Surveillance Recommendations\n- Initially every 3 months, then spaced to every 6-12 months\n- Physical exam and laboratory monitoring\n- Surveillance imaging NOT recommended for asymptomatic patients\n- If imaging indicated, typical interval is 12 months\n\n### Clinical Trial Consideration\n- Clinical trials should always be considered at all treatment decision points\n- For assistance finding a clinical trial, contact CancerClinicalTrialNavigation@nyu.edu\n\nThis clinical pathway represents a structured, evidence-based approach to follicular lymphoma management. Individual patient factors, comorbidities, preferences, and goals of care should be incorporated into all treatment decisions through shared decision-making.",
    "thinking": "Based on the analyses of pages 2-7 of the Follicular Lymphoma Clinical Pathway document, I'll create a comprehensive, structured summary that covers the entire clinical pathway. I'll organize the information logically, emphasizing key decision points, diagnostic criteria, treatment options, and clinical workflows.\n\n# Comprehensive Summary of Follicular Lymphoma Clinical Pathway\n\nI'll structure this summary to follow the natural progression of patient care:\n1. Introduction and Overview\n2. Presumptive Conditions and VA Service Connection\n3. Diagnostic Approach and Initial Assessment\n4. Treatment Pathways by Disease Stage and Line of Therapy\n   - First-Line Treatment\n   - Second-Line/Relapsed Disease\n   - Multiply Relapsed Disease\n5. Molecular Testing and Precision Medicine\n6. Supportive Care and Surveillance\n\nLet me develop each section in detail:\n\n## 1. Introduction and Overview\nFollicular lymphoma (FL) is a common indolent B-cell non-Hodgkin lymphoma characterized by a relapsing and remitting disease course. This clinical pathway provides evidence-based guidance for the diagnosis, treatment, and management of patients with follicular lymphoma at various stages of disease.\n\n## 2. Presumptive Conditions and VA Service Connection\nVeterans with follicular lymphoma may qualify for VA disability compensation through presumptive service connection under specific circumstances:\n\n### Presumptive Eligibility Categories:\n1. **Atomic Veterans with Exposure to Ionizing Radiation**\n   - Lymphomas (other than Hodgkin's disease) are covered conditions\n\n2. **Gulf War and Post 9/11 Veterans**\n   - Eligible if diagnosed with lymphoma of any type AND served:\n     * On/after September 11, 2001 in: Afghanistan, Djibouti, Egypt, Jordan, Lebanon, Syria, Uzbekistan, or Yemen\n     * OR\n     * On/after August 2, 1990 in: Southwest Asia theater of operations or Somalia\n\n3. **Southwest Asia Theater Definition**\n   - Iraq, Kuwait, Saudi Arabia\n   - Neutral zone between Iraq and Saudi Arabia\n   - Bahrain, Qatar, United Arab Emirates, Oman\n   - Gulf of Aden, Gulf of Oman, Persian Gulf, Arabian Sea, Red Sea\n   - Airspace above these locations\n\nFor qualifying veterans, service connection is automatically presumed without requiring proof of connection between the condition and military service.\n\n## 3. Diagnostic Approach and Initial Assessment\n\n### Initial Diagnostic Workup\n1. **Histopathological Assessment**\n   - Lymph node excisional biopsy preferred\n   - Grade determination critical:\n     * Grade 1-3a: Follow standard follicular lymphoma pathway\n     * Grade 3b: Follow DLBCL (Diffuse Large B-Cell Lymphoma) pathway\n\n2. **Imaging Studies**\n   - Cross-Sectional Imaging: CT neck, chest, abdomen, and pelvis with IV contrast or FDG-PET/CT\n   - PET/CT recommended if transformation concern exists\n\n3. **Laboratory Testing**\n   - Complete blood count (CBC) with differential\n   - Comprehensive metabolic panel (CMP)\n   - Uric acid, LDH\n   - Hepatitis testing: HBsAg, HBcAb, HBsAb, HCV antibody\n   - HIV testing\n\n4. **Staging Procedures**\n   - Bone marrow biopsy and PET/CT should be performed to confirm limited stage\n   - Assess for transformation to aggressive lymphoma if clinically suspected\n\n### Assessment for Transformation\n- If transformation concern exists:\n  * Perform PET/CT and biopsy of FDG-avid site\n  * If transformation confirmed \u2192 Follow DLBCL pathway\n  * If transformation not confirmed \u2192 Continue with FL pathway\n\n## 4. Treatment Pathways by Disease Stage and Line of Therapy\n\n### First-Line Treatment\n\n#### Stage I or Contiguous Stage II (Limited Stage)\n- **Option 1**: Radiation therapy (24-30 Gy)\n- **Option 2**: Observation with monitoring every 3-6 months\n\n#### Advanced Disease (Not Stage I or Contiguous Stage II)\n- **Step 1**: Evaluate for indications for therapy\n  * **Indications for Initiating Therapy**:\n    - Local symptoms due to nodal disease\n    - Reduced organ function due to nodal disease\n    - B-symptoms (fever, weight loss, night sweats)\n    - Cytopenias (Hgb < 10 g/dL, platelets <100,000/mm\u00b3)\n    - Increase in disease tempo\n\n- **Step 2**: Treatment decision\n  * **If indications for therapy present**:\n    - Conduct shared decision-making with patient\n    - **Treatment options**:\n      * Lenalidomide and rituximab (18 cycles)\n      * Bendamustine and obinutuzumab (6 cycles)\n    - Monitor every 3-6 months after treatment\n\n  * **If no indications for therapy**:\n    - Observation with monitoring every 3-6 months\n\n- **Step 3**: Consider maintenance therapy\n  * Rituximab maintenance (every 8 weeks for 24 months)\n  * Improves progression-free survival\n  * Consider individual risks and benefits\n\n### Second-Line/Relapsed Disease Treatment\n\n#### Initial Assessment\n- Clinical/laboratory workup\n- Review of previous therapy\n- Assessment for transformation\n\n#### Treatment Pathway Decision Points\n1. **Evaluate for clinical trial eligibility**\n   - If eligible \u2192 Enroll in clinical trial\n   - If not eligible \u2192 Continue to standard treatment options\n\n2. **Prior treatment history assessment**:\n\n   **a. Previous alkylating agent + anti-CD20**:\n   - Options:\n     * Bendamustine + rituximab (if prior therapy >24 months ago)\n     * Lenalidomide + rituximab\n     * PI3K inhibitors (idelalisib, copanlisib, duvelisib)\n     * Radioimmunotherapy (if eligible)\n     * EZH2 inhibitor (for patients with EZH2 mutation)\n\n   **b. Previous bendamustine + anti-CD20**:\n   - Options:\n     * CHOP/CVP if >24 months since prior treatment\n     * Lenalidomide + rituximab\n     * PI3K inhibitors\n     * EZH2 inhibitor (for patients with EZH2 mutation)\n\n   **c. Previous CHOP/CVP + anti-CD20**:\n   - Options:\n     * Bendamustine + rituximab (if >24 months since prior therapy)\n     * Lenalidomide + rituximab\n     * PI3K inhibitors\n     * EZH2 inhibitor (for patients with EZH2 mutation)\n\n3. **Post-Treatment Evaluation**:\n   - Complete/partial response \u2192 Consider maintenance therapy or observation\n   - No response/progression \u2192 Proceed to multiply relapsed pathway\n\n### Multiply Relapsed Disease Treatment\n\n#### Initial Assessment\n- Cross-sectional imaging\n- Biopsy of accessible target tissue\n- Assessment for transformation\n\n#### Treatment Algorithm\n1. **If transformation present**:\n   - Early referral for cellular therapy (stem cell transplant or CAR-T)\n   - Follow DLBCL pathway\n\n2. **If no transformation**:\n   - Assess if prior therapy was low intensity\n   \n   **If prior therapy was NOT low intensity**:\n   - Evaluate if lymphoma is unfavorable\n     \n     **If unfavorable lymphoma**:\n     - Patient preference and shared decision making\n       \n       **If patient agrees to treatment**:\n       - Treatment options:\n         * Bendamustine-rituximab (4 cycles), OR\n         * Lenalidomide-rituximab\n       - Evaluate if candidate for cellular therapy\n         \n         **If candidate for cellular therapy**:\n         - Early referral for stem cell transplant or CAR-T therapy\n         - Assess for EZH2 mutation\n           * If EZH2 mutation present \u2192 Tazemetostat\n           * If No EZH2 mutation \u2192 Zandelisib + obinutuzumab\n         \n         **If not candidate for cellular therapy**:\n         - Mosunetuzumab\n         - Monitor for progression\n     \n     **If not unfavorable lymphoma**:\n     - Follow Indolent Follicular Lymphoma pathway\n\n#### Definitions for Multiply Relapsed Disease Management\n- **Low Intensity Therapies**: Includes INT, single agent anti-CD20 antibody, and/or chlorambucil\n\n- **Unfavorable** defined as:\n  * Relapsed after anti-CD20 antibody, systemic chemotherapy, and lenalidomide, OR\n  * Progression <24 months from all prior treatments\n\n- **Candidate for Cellular Therapy** defined as:\n  * ECOG performance status 0-1\n  * Few or controlled comorbidities\n  * Younger age (typically <70 years)\n  * Patient and caregiver willing to relocate to cell therapy site if needed\n\n## 5. Molecular Testing and Precision Medicine\n\n### Molecular Testing by Clinical Scenario\n\n#### A. Suspected Pediatric-Type Follicular Lymphoma\n- **Specimen**: Bone Marrow Biopsy, Lymph Node Biopsy, or Blood\n- **Testing Required**:\n  * **IHC**: BCL2 and BCL6\n  * **FISH**: t(14;18), BCL6, IRF4 or IGH rearrangements, 1p36\n- **Testing Provider**: Local VA or locally contracted vendor\n- **NPOP Coverage**: No\n\n#### B. Suspected Large B-Cell Lymphoma with IRF4 Rearrangement\n- **Specimen**: Bone Marrow Biopsy, Lymph Node Biopsy, or Blood\n- **Testing Required**:\n  * **IHC**: BCL2, BCL6, CD10 and MUM1\n  * **FISH**: IRF4/MUM1 cryptic rearrangement with IGH\n- **Testing Provider**: Local VA or locally contracted vendor\n- **NPOP Coverage**: No\n\n#### C. Multiply Relapsed Follicular Lymphoma\n- **Specimen**: Bone Marrow Biopsy, Lymph Node Biopsy, or Blood\n- **Testing Required**:\n  * **Molecular**: EZH2 mutation analysis\n- **Testing Provider**: Tempus or Foundation\n- **NPOP Coverage**: Yes\n\n## 6. Supportive Care and Surveillance\n\n### Supportive Care\n- **Hepatitis B Management**:\n  * Test HBV DNA if HBsAg or HBcAb positive\n  * Prescribe entecavir if HBsAg or HBcAb positive\n\n- **Other Infectious Disease Management**:\n  * Hepatitis C antiviral treatment if appropriate\n  * COVID and pneumococcal vaccination recommendations\n  * Consider VZV/HSV and PJP prophylaxis for transplant candidates or fludarabine-regimens\n\n- **Specific Regimen-Related Prophylaxis**:\n  * LVF prophylaxis as required with anthracyclines\n  * VTE prophylaxis required with lenalidomide\n  * G-CSF growth factor support for age >70 years, pre-existing leukopenia, recent prior chemotherapy\n\n### Surveillance\n- **Frequency**:\n  * Initially every 3 months, then spaced to every 6-12 months\n  * Physical exam and labs\n  * Surveillance imaging is not recommended for asymptomatic patients\n  * For those requiring imaging, typical frequency is at 12-month intervals\n\n### Clinical Trial Consideration\n- Clinical trials should always be considered at all stages of treatment\n- For assistance finding a clinical trial, contact CancerClinicalTrialNavigation@nyu.edu"
  }
}